Zhejiang Taimei Medical Technology Co., Ltd. (TAIMEI TECH) disclosed that it repurchased 40,200 H-shares on 29 June 2026 via on-market transactions on the Hong Kong Stock Exchange.

The buyback, executed within a price range of HKD 6.37–6.42 and costing HKD 0.26 million, was conducted under the repurchase mandate approved on 23 June 2026. All shares repurchased have been retained as treasury shares.

Key post-transaction metrics:

• Issued shares (excluding treasury shares) decreased to 199.70 million, down 0.02% from 199.74 million prior to the repurchase. • Treasury shares rose to 0.89 million from 0.85 million. • Total issued shares remained unchanged at 200.59 million, as the repurchased shares have not been cancelled. • Cumulative repurchases under the current mandate total 469,000 shares, equivalent to 0.23% of the share count when the mandate was granted. • The company is restricted from issuing new shares or disposing of treasury shares until 29 July 2026, in line with Hong Kong listing rules.

TAIMEI TECH affirms that the repurchase complied with both Hong Kong Stock Exchange regulations and its previously published Explanatory Statement dated 1 June 2026.